Verrica Pharmaceuticals (VRCA) Operating Income (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Operating Income of -$9.7 million for Q1 2026, down 19.5% year-over-year from -$12.1 million in Q1 2025, and down 35.08% quarter-over-quarter from -$7.2 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Operating Income (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Operating Income history runs 10 years deep, the most recent figure standing at -$9.7 million for Q1 2026.
- In Q1 2026, Operating Income fell 19.5% year-over-year to -$9.7 million; the TTM figure through Mar 2026 stood at -$13.8 million (up 75.17% YoY), while the FY2025 annual figure was -$12.2 million, up 81.52% from the prior year.
- Operating Income for Q1 2026 stood at -$9.7 million, down from -$7.2 million in the prior quarter.
- The five-year high for Operating Income was $1.6 million in Q3 2025, with the low at -$23.9 million in Q3 2023.
- The 5-year median for Operating Income is -$9.1 million (2022), against an average of -$10.3 million.
- Peak annual rise in Operating Income reached 112.3% in 2022, while the deepest fall reached 12450.0% in 2022.
- Verrica Pharmaceuticals' Operating Income stood at -$6.2 million in 2022, then sank by 272.5% to -$23.1 million in 2023, then soared by 50.68% to -$11.4 million in 2024, then soared by 36.97% to -$7.2 million in 2025, then sank by 35.08% to -$9.7 million in 2026.
- Business Quant data shows VRCA's Operating Income at -$9.7 million in Q1 2026, -$7.2 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Verrica Pharmaceuticals | 104.71 Mn | 93.51 Mn | - | -13.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.10 Mn |
| Mar 31, 2026 | -9.72 Mn |
| Dec 31, 2025 | -7.19 Mn |
| Sep 30, 2025 | 1.63 Mn |
| Jun 30, 2025 | 1.51 Mn |
| Mar 31, 2025 | -8.13 Mn |
| Dec 31, 2024 | -11.41 Mn |
| Sep 30, 2024 | -20.70 Mn |
| Jun 30, 2024 | -15.21 Mn |
| Mar 31, 2024 | -18.60 Mn |
| Dec 31, 2023 | -23.14 Mn |
| Sep 30, 2023 | -23.92 Mn |
| Jun 30, 2023 | -11.62 Mn |
| Mar 31, 2023 | -7.09 Mn |
| Dec 31, 2022 | -6.21 Mn |
| Sep 30, 2022 | 1.45 Mn |
| Jun 30, 2022 | -9.12 Mn |
| Mar 31, 2022 | -7.41 Mn |
| Dec 31, 2021 | -8.47 Mn |
| Sep 30, 2021 | -11.77 Mn |